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Abstract: The human gut is a safe environment for several microbes that are symbiotic and important
for the wellbeing of human health. However, studies on gut microbiota in different animals
have suggested that changes in the composition and structure of these microbes may promote gut
inflammation by releasing inflammatory cytokines and lipopolysaccharides, gut-wall leakage, and may
affect systemic inflammatory and immune mechanisms that are important for the normal functioning
of the body. There are many factors that aid in the gut’s dysbiosis and neuroinflammation, including
high stress levels, lack of sleep, fatty and processed foods, and the prolonged use of antibiotics.
These neurotoxic mechanisms of dysbiosis may increase susceptibility to Alzheimer’s disease (AD)
and other neurodegenerative conditions. Therefore, studies have recently been conducted to tackle
AD-like conditions by specifically targeting gut microbes that need further elucidation. It was
suggested that gut dyshomeostasis may be regulated by using available options, including the use of
flavonoids such as anthocyanins, and restriction of the use of high-fatty-acid-containing food. In this
review, we summarize the gut microbiota, factors promoting it, and possible therapeutic interventions
especially focused on the therapeutic potential of natural dietary polyflavonoid anthocyanins.
Our study strongly suggests that gut dysbiosis and systemic inflammation are critically involved
in the development of neurodegenerative disorders, and the natural intake of these flavonoids may
provide new therapeutic opportunities for preclinical or clinical studies.
Keywords: natural polyflavonoids; gut dysbiosis; systemic inflammation; neuroinflammation;
memory impairment; Alzheimer’s disease
1. Introduction
The microbial population living in human and animal intestines is termed as the gut microbiota
(formerly called gut flora). Gut microbiota are trillions of micro-organisms, including at least 1000
different species of known bacteria with more than three million genes [1]. The interaction between
human health and the gut microbiota is well-documented [2]. The gut microbiota comprises two
phyla, Bacteroidetes and Firmicutes. At the embryonic stage, the gut microbiota appears disorganized,
while by the age of three, it starts to look similar to adult flora [3]. Several main microbiota functions
have been explored, including the synthesis of amino acids and vitamins that play a major role in the
circulation of steroid molecules (including bile acids and sex hormones), boosting the immune system
and production of different bioactive compounds [4,5].
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In this comprehensive review, we summarize the current research, highlighting the role of the gut
microbiota in the pathogenesis of neuroinflammation and AD-like pathologies. The literature search
was comprehensive, including both published and unpublished articles. We documented the search
process, kept track of the decisions that were made for each article, and screened and extracted the
conclusions. Moreover, we summarized all current research from more than 350 research and review
articles, showing the interaction between gut microbiota and neurocognitive function. In summary,
our findings suggest that gut microbiota have a significant impact on the pathogenesis of Alzheimer’s
disease, which may be significantly delayed with the administration of anthocyanin.
1.1. Normal Gut-Microbiota Functions in Human Body
Colonic bacteria can ferment complex carbohydrate-yielding short-chain fatty acids (SCFAs)
in which propionate, butyrate, and acetate are predominantly found in the gastrointestinal tract
(GI), with a ratio of 1:1:3, respectively, performing different cellular functions, such as gene
expression, chemotaxis, differentiation, and proliferation. Acetate is generated by most gut anaerobes,
whereas propionate and butyrate are produced by different classes of gut bacteria following distinct
molecular pathways. Butyrate is generated from carbohydrates via the acetoacetyl–CoA and
glycolytic pathway, whereas propionate is formed from two pathways, the succinate or propanediol
pathway [6–11].
Propionate gluconeogenesis can be stimulated by the liver, while acetate and butyrate are lipogenic.
Propionate and butyrate are histone deacetylase (HDAC) inhibitors, which epigenetically modulate
the expression of certain important genes. SCFAs confer a key role in the regulation of immunity
and inflammatory conditions. They also affect the release of cytokines, for example, by activating
the release of interleukin IL-18, that is involved in the restoration and preservation of the epithelial
structure. SCFAs were shown to regulate appetite and energy intake via various mechanisms [12–19].
GI microbes are also helpful in the synthesis of pivotal vitamins that cannot be produced by
the host organisms. Vitamin B12, which is crucial for the body, is produced by lactic acid bacteria
and is not synthesized by animals and plants. Other vitamins, such as folate that regulates the
metabolic processes of the hosts, including DNA synthesis and repair, are produced by Bifidobacteria.
A major immune shortage shown by germfree animals is the lack of CD4+ T-cell levels. This dearth
can be recovered by the administration of polysaccharide A to germfree mice from the capsule of
Bacteroides fragilis. This mechanism is conducted through pattern-recognition receptors (PRRs), such as
toll- or NOD-like receptors, which recognize molecules that are induced by intestinal microbiota.
These processes may attenuate certain inflammatory gut diseases by boosting the beneficial suppression
of pathogenic bacteria, or regulating immune cells or PRRs [20,21]. In Crohn’s disease, individuals
display mucosal dysbiosis, which may be pointed out by the reduced diversity of main microbes and
F. prausnitzii [22–29].
Studies have suggested that F. prausnitzii contains an anti-inflammatory protein that inhibits
the nuclear factor–κB (NF-κB) pathway in intestinal epithelial cells in animals. NF-κB represents
a family of inducible transcription factors, that regulate a large number of genes involved in
inflammatory processes. This family is composed of five structurally related members that
mediate the transcription of target genes by binding to a specific DNA element, the κB enhancer,
as various hetero- or homodimers [30]. Normally, NF-κB is locked in the cytoplasm by an inhibitory
protein of the IκB family. Upon activation, IκB is phosphorylated by the IκB kinase complex
(IKK), before undergoing degradation by the proteasome. Then, free NF-κB translocates to the
nucleus to turn on a large number of genes involved in proinflammatory processes at the site of
tissue damage [31]. Different studies have suggested that the gut microbiota plays a role in the
inhibition of NF-κB [32,33]. Moreover, Salmonella typhimurium and Clostridium difficile utilize sialic
acid, released by the gut microbiota, which favors their expansion in the gut [34–39]. The GI
microbiota, through its metabolites, promotes the production of different antimicrobials, which include
antimicrobial proteins (AMPs) such as cathelicidins and C-type lectins. Other mechanisms through
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which the gut microbiota can overcome pathogen growth are by promoting mucosal secretory IgA
(SIgA). Moreover, pattern-recognition-receptor–microbe-associated-molecular-pattern (PRR–MAMP)
interactions regulate several signaling tools that are crucial for promoting mucosal-barrier function
and the production of AMPs, thus adding to host defense against pathogenic microbes [3,40–43].
1.2. Dysbiosis and Its Pathogenesis Factors
Dysbiosis is a term for a microbial imbalance inside the body, such as an impaired microbiota.
There are many factors involved in dysbiosis that are given in Figure 1 [44].
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1.2.1. Congenital Factors
The microbial population can be affected by numerous factors, including mode of birth, nutrition,
antibiotic exposure, stress, age, and degree of hygiene. For example, babies born through the vagina
acquire the mother’s vaginal microbial flora, including Escherichia coli, Lactobacillus, Bifidobacterium,
and Bacteroides. Those born via Cesarean section, on the other hand, have a high risk of skin-related
bacterial invasion, including Staphylococcus species that continue throughout infancy [45–52].
1.2.2. Dietary Factors
The effects of diet on the structure of gut microbes have been evaluated during the initial phase of
colonization, as breastfed children have a greater number of Bifidobacteria spp, while formula-milk-fed
children have higher levels of Bacteroides spp. Generally, a change in diet could induce 57% of total
changes in gut microbiota, whereas congenital changes account for less than 12%, showing that diet has
a prominent role in the structuring of the gut microbiota. The Western diet, which is rich in sugar and
fat, causes dysbiosis, and affects the GI tract and the immune system [53–55]. The effects of a high-fat
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diet (HFD) on mice were also evaluated, where they were fed with a HFD for three months and showed
a decline in the growth of Bacteroidetes, while the levels of Firmicutes, Proteobacteria, and Actinobacteria
were markedly upregulated [56–61].
1.2.3. Effects of Chemical Exposure on Gut Microbiota
It was previously concluded that exposure to chemicals causes marked dysbiosis in the gut,
which includes the augmented production of the Firmicutes phylum and reduced Bacteroidetes
production. Similarly, the chronic administration of corticosterone causes gut dysbiosis. Furthermore,
recent studies have suggested that the lack of intestinal alkaline phosphatase (IAP) induces dysbiosis,
and elevates the inflammation and penetrability of the intestinal lining of newborns [62–66].
1.2.4. Effects of General Stress on Gut Microbiota
Stress is a disturbance in body homeostasis, due to different kinds of factors, such as psychological
and environmental stimuli, and physical stress, which provoke physiological and behavioral responses
to reinstate homeostasis. Stress has a variety of biological effects, such as modulation of microbes in
the GI tract. [67–74]. Here, we present recent studies associated with stress-induced changes in GI
microbiota structure and composition. Stress types include sleep deprivation, psychological stress,
circadian disturbance, environmental pathogens, environmental stress, pollutants, and diet, which were
selected for their direct effect on environmental physiology and military personnel [75–79].
1.2.5. Mental Stress and Gut Microbiota
Physiological stress may be induced by different means, including social deprivation and water
restraint. These induce a disturbance in the body that causes inflammation, modulates immunity, alters
GI function, and produces anxiety-like behaviors. From a military perspective, social defeat stress (SDS)
is the most accepted model [80–85]. Using the SDS model in a study, 2 h SDS was enough to change
mucosa-related microbes in mice, reducing Lactobacillus reuteri. When they were repeatedly exposed
for 2 h over 6 days, this caused the higher attenuation of Lactobacillus. The relationship between gut,
brain, and gut microbiota is bidirectional, where stress-triggered activation of the sympathetic nervous
system (SNS) and the hypothalamic–pituitary–adrenal (HPA) axis affects gastrointestinal (GI)-tract
microbes. Later, all these affect the central nervous system, either through the enteric nervous system,
via spinal and vagal nerves, or via blood circulation when they gain entry to the blood stream and
cross the blood–brain barrier [86–89].
1.2.6. Altitude and Temperature Effects on Normal Gut Microbiota
It is commonly reported that the consequences of high altitude (2500 m) may affect the GI
system (GIS). The symptoms that were observed because of hypobaric hypoxia are loss of appetite,
indigestion, nausea, vomiting, gas, and abdominal pain. It has been reported that low oxygen delivery
to the GI affects motility, because intestinal epithelia cells need oxygen-saturated blood for their
normal physiological functions. An increase in the number of proinflammatory Enterobacteriaceae
with increased inflammation and a decrease in the number of Bifidobacteria was found during a trip to
Himalaya. Furthermore, it has been demonstrated that soldiers working or training at 3505 m altitude
may decrease aerobic counts, while increasing beneficial and harmful micro-organisms [90–95].
A recent study showed that acute cold promotes alteration in murine gut microbiota [96–100].
Several studies indicated that the effect of cold on the human gut microbiota could be useful by
promoting cold tolerance, which needs more exploration [101–103].
1.2.7. Intestinal Infection (Enteric Pathogens) Accelerates Gut Dysbiosis and Alters
Gastrointestinal-Wall Integrity
A major type of diarrhea is called traveler’s diarrhea (TD), which commonly occurs in
military personnel and is caused by enteroaggregative and enterotoxigenic E. coli Salmonella spp,
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Shigella, and Campylobacter jejuni. These agents cause diarrheal infections through the physical
disruption of the gut barrier and immune-system disturbance, which leads to disturbing the gastric
environment [104–110]. Some medically recommended antibiotics that are used for the treatment
of infectious diarrhea and TD are azithromycin; levofloxacin enables the growth of opportunistic
pathogens [111–116].
1.2.8. Environmental Pollution and Toxins Affect Animal Health and Increase the Number of
Opportunistic Gut Microbes
Industrial chemicals and toxic industrial materials make the environment and air deleterious
and unfit for survival. It is well known that burn pits are used to hide and destroy solid waste,
particularly in military sites that carry toxic compounds, such as polycyclic aromatic hydrocarbons
(PAHs), polychlorinated compounds, and particulates. A rodent model reported that exposure of adult
mice to cadmium for 10 weeks changed gut-microbiota composition at the phylum and family levels.
This same model also proposed that an increase in Bacteroidaceae boosts serum lipopolysaccharides
(LPS). Moreover, it showed that the oral administration of B[a]P to experiment mice for 28 days resulted
in moderate gastric inflammation and microbial-community shifts that included a decline in the level
of anti-inflammatory taxa (e.g., Lactobacillus and Akkermansia), and an increase in the level of numerous
inflammatory taxa [117–120].
1.2.9. Effects of Noise on Gut Dysbiosis and Normal Microflora
When rodents were exposed to acoustic stress, intestinal tight-junction protein expression
was decreased, intestinal permeability was increased, GI motility was changed, inflammation and
intestine-tissue damage increased, and gastric-ulcer induction was observed. However, a study
demonstrated that exposure of aged mice to severe noise for 4 h/day up to 30 days changed
cecal microbiota, which was characterized by an increase in Bacteroidetes/Firmicutes ratio, associated
with decreased expression of tight-junction proteins in the colon and hippocampus, inflammation,
and Alzheimer’s-like cognitive impairments [121–129].
1.2.10. Gut Dysbiosis Induces Neuroinflammation and Alzheimer’s Disease Pathology
The lipopolysaccharides are secreted by gut bacteria during dysbiosis that exaggerate Alzheimer’s
disease pathology, via the activation of amyloidogenic signaling pathways. Studies have suggested
that bacterial-surface lipopolysaccharides bind with microglial receptors (TLR2, TLR4, and CD14)
and activate the downstream NF-κB transcription factor. The activation of NF-κB producing
proinflammatory cytokines that initiate neuroinflammatory responses. This neuroinflammatory
response and reactive microglia activate various Alzheimer’s pathways, such as beta-secretase 1
(BACE1; Figure 2) [130–136].
Cells 2020, 9, 853 6 of 21
Cells 2020, 9, x FOR PEER REVIEW 6 of 22 
 
 
Figure 2. Increased beta-secretase 1 (BACE1) enzyme activity causes senile plaque formation. 
Increased BACE1 activity (when NF-κB transcription factor binds with its promoter region) causes 
abnormal APP cleavage that produces a burden of amyloid beta proteins. Consequences of amyloid 
beta plaques include Alzheimer’s disease development. 
However, a study revealed that lipopolysaccharides, endotoxins, and pathogens disrupt the gut 
and blood–brain barrier (BBB) tight junctions, and enter the brain, for example Salmonella, E. coli, and 
Citrobacter produce Aβ. In the brain, misfolding amyloid proteins may be triggered by an exposure 
to microbial communities. A prion-like mechanism is the same as the propagation and formation of 
Aβ seeds [134,137–141]. One possibility is that epithelial cells of mucosa-associated lymphoid tissue 
collect and pass it to the parasympathetic neurons of the vagus nerve and enteric nervous system, 
from where they may gain entry to the CNS through retrograde axonal transport. Dysregulation of 
these molecules can lead to neurotoxicity and chronic inflammation. 
1.3. Daily Use of Natural Dietary Anthocyanins Increases Beneficial-Microbe Population, Prevents Leaky 
Gut, and Inhibits Circulatory Inflammagen (LPS) and Proinflammatory Cytokines 
Anthocyanins belong to flavonoids, are soluble in water, and are polyphenolic pigments that 
give color to food. There are some fruits and vegetables that are rich in anthocyanins, such as grapes, 
black plums, and blueberries, red and black rice, and black soybeans. The amount and composition 
of anthocyanins in different fruits and vegetables range from 0.1% to 1% (Figure 3).  
Figure 2. Increased beta-secretase 1 (BACE1) enzyme activity causes senile plaque formation.
Increased BACE1 activity (when NF-κB transcription factor binds with its promoter region) causes
abnormal APP cleavage that produces a burden of amyloid beta proteins. Consequences of amyloid
beta plaques include Alzheimer’s disease development.
However, a study revealed that lipopolysaccharides, endotoxins, and pathogens disrupt the gut
and blood–brain barrier (BBB) tight junctions, and enter the brain, for example Salmonella, E. coli,
and Citrobacter produce Aβ. In the brain, misfolding amyloid proteins may be triggered by an exposure
to microbial communities. A prion-like mechanism is the same as the propagation and formation of
Aβ seeds [134,137–141]. One possibility is that epithelial cells of mucosa-associated lymphoid tissue
collect and pass it to the parasympathetic neurons of the vagus nerve and enteric nervous system, from
where they may gain entry to the CNS throug retrograde axonal transport. Dysregulation of these
molecules can lead to neurotoxicity and chroni inflammation.
1.3. Daily Use of Natural Dietary Anthocyanins Increases Beneficial- icrobe Population, Prevents Leaky Gut,
and Inhibits Circulatory Inflammagen (LPS) and Proinflammatory Cytokines
Anthocyanins belong to flavonoids, are soluble in water, and are polyphenolic pigments that
give color to food. There are some fruits and vegetables that are rich in anthocyanins, such as grapes,
black plums, and blueb rries, red and black rice, and black soybeans. The amount and co siti of
anthocyanins in different fruits and vegetables range from 0.1% to 1% (Figure 3).
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Figure 3. Natural dietary Anthocyanin sources. Various fruits and vegetables are rich sources of natural
dietary anthocy nin.
Berries are rich source of anthoc s, so they may help in differe t functions of the body,
as highlighted previously [1 ].
Furthermore, enzymolysis, oxidation, and cli atic factors like light, temperature, and pH can
change the level of anthocyanins. Acidic conditions are better for the stability of anthocyanins.
In most cases though, it is degraded at high pH. Anthocyanins are naturally present in plants as
glycosides carrying glucose, galactose, arabinose, rhamnose, and xylose [144–153]. The unstable form
of deglycosylated anthocyanins is called anthocyanidins, which are very rare in nature. The peculiar
electron distribution and presence of flavylium ion are the reasons for anthocyanidin instability. On the
basis of chemical structure, 700 anthocyanins and 27 aglycones have so far been recognized. The basic
structure of anthocyanin comprises a C-6 (A ring)-C-3 (C ring)-C-6 (B ring) carbon skeleton with different
numbers of sugars and hy roxyl groups, and varying degrees of methylation [144,146,153–157]. I was
established that tight junctions provide a paracellular barrier that only allows select molecules into the
intercellular space between epithelial cells (Figure 4).
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Figure 4. Leaky gut contributes to circ inflammagens and proinflammatory cytokines.
Opportunistic ba teria produce various toxins a l saccharides that, in turn, cause intestin l-wall
inflammation that results in a leaky gut. Epithelial-cell infla mation also leads to loss of tight
junctions that provide opportunities for undigested food particles, toxins, and inflammatory cytokines
to enter bloodstream. Toxins and lipopolysaccharide (LPS)-containing blood later enter brain via
blood–brain-barrier disruption.
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Cellular adhesion occurs because of occluding-regulated paracellular permeability. A classic
TJ marker, ZO-1, works as an anchor and contributes to connecting occludin, claudin, and actin
cytoskeletons to increase the epithelial barrier [158–169]. An in vivo study was carried out on
rodents, where adult mice received 100 mg/kg black-rice extract per os (P.O.) for five days, in order
to induce colitis, which indicated that mice that received black-rice extract had fewer histological
lesions in their mucosa, as compared to dextran sodium sulfate-treated mice. It was suggested that
anthocyanins prevent starch digestion by inhibiting the α´-amylase enzyme. When this undigested
starch reaches the large intestine, it provides energy to probiotic bacteria, including Lactobacilli,
Bifidobacteria, and Streptococci, which later on improves health conditions [167,170–177].
1.4. Anthocyanins Mitigate Gut Dysbiosis that Induces Neuroinflammation and Alzheimer’s Pathology
It was reported that LPS can enter the bloodstream via a damaged intestinal epithelium during an
enteric-dysbiosis failure. The increase in the abundance of opportunistic pathogens could cause an
increase in serum LPS levels. LPS further activates inflammatory pathways, including TLR4/NF-κB,
which, in turn, leads to the release of proinflammatory cytokines, such as TNF-α´, IL-1β, and CO2, that
then enter the bloodstream via a leaky gut (Figure 5) [178–180].
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Figure 5. Gut dysbiosis causes epithelial inflammation. When harmful, particularly E. coli,
Gram-negative bacteria secrete lipopolysaccharides that activate the TLR4 pathway and later on
cause intestinal-wall and epithelial inflammation. This lipopolys ccharide not only ctivat s the TLR4
signal ng pathw y, but also micr glial and strocyte cells in th gut, that then secre e proinflammatory
cytokines. These proinflammatory cytokines later gain entry to the bloodstr am via a leaky gut.
This serum LPS then disrupts the blood–brain-barrier (BBB) and enters the brain, where it reactivates
microglia, and various inflammatory and amyloid genic pathways.
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Previous studies reported that the abnormal cleavage of the amyloid beta protein by β-secretase
results in amyloid beta plaque formation. Increased amyloid beta plaques accelerate neuronal cell death
and Alzheimer’s pathology [181–183]. Moreover, gut bacteria populating the microbiome were shown
to produce amyloids and other immunogenic mediators that contribute to the modulation of signaling
mechanisms implicated in neuroinflammation, brain Aβ deposition, and AD pathogenesis [184].
To explain how gut microbiota might contribute to AD pathogenesis, it was hypothesized that
bacteria-derived amyloids leak from the gastrointestinal tract and accumulate at system and brain
levels [185].
Here, we summarized the neuroinflammation-mediated amyloid beta burden and Alzheimer’s
pathology because, in dysbiosis, the opportunistic bacterial component (LPS) is prominently
generated inside the gut, which later gains entry to the brain via the blood and causes a
neuroinflammation-mediated amyloid beta burden (Figure 6) [186,187].
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Figure 6. Gut-microbiota-secreted polysaccharides and other toxins cause neuroinflammation and
Alzheimer’s disease development. When circulatory lipopolysaccharides enter the brain, it activates
inflammatory pathways and increases the number of reactive microglia. Increased inflammatory
cytokines and NF-κB increase APP and amyloid beta protein cleavage and accumulation, and cause
Alzheimer’s disease development.
It has been reported that LPS is the ligand of the TLR4 receptor that exists on microglia cells.
When LPS bind with TLR4, it activates the inflammatory cascade by translocating the downstream
NF-κB to the nucleus. Once NF-κB phosphorylates, it binds with proinflammatory cytokine (TNF-α´,
IL-1β, and COX2) as a result, increases the neuroinflammation (Figure 7).
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Figure 7. Anthocyanins prevent inflammatory and amyloid genic pathways in the central nervous
system. When circulatory lipopolysaccharides and inflammatory cytokines gain entry to the brain,
toll-like receptor 4 on microglia is activated, which subsequently leads to the activation of nuclear
factor kappa B (NF-κB). After NF-κB phosphorylation and translocation to the nucleus, it goes
on to bind with proinflammatory cytokine genes, that results in the production and release of
proinflammatory cytokines. NF-κB also binds with the promoter region of BACE1 that produces
β-secretase enzymes. Increased BACE1 activities later result in abnormal APP cleavage. Chronic
deposition of amyloid beta proteins in the brain causes amyloid beta plaque formation and neuronal
cell death. Amyloid beta plaques also deregulate pre- and postsynaptic proteins, which results in
dementia and memory impairment.
Ali T and Khan, M.S. et al. recently reported that anthocyanins could significantly ameliorate
the expression of proinflammatory cytokines and ROS/JNK, thus preventing neuroinflammation
and Alzheimer’s pathology [188–198]. Moreover, a study has shown the rescuing effects of
anthocyanin against Alzheimer’s disease pathology (APP, BACE-1, Aβ, and P-tau) and synapsis-related
functions in Aβ1-42-injected mice [199]. The effects of anthocyanin against gut-dysbiosis-induced
neuroinflammation are in accordance with previously conducted studies, showing that nutrients have
a significant effect against microbiota-induced neurocognitive disorders [200].
2. Conclusions and Future Perspectives
In our study, we focused on gut dysbiosis that induces systemic toxins, inflammagen-mediated
neuroinflammation, and Alzheimer’s pathology. We summarized that gut dysbiosis not only induces
gastrointestinal disorder, particularly epithelial inflammation, tight-junction disruption, and leaky gut,
Cells 2020, 9, 853 11 of 21
but also contaminates the circulatory blood that results in BBB disruption, neuroinflammation-mediated
Alzheimer’s pathology, and memory dysfunction (Figure 8).
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